【摘要】 表皮生长因子受体（epidermal growth factor receptor, EGFR）酪氨酸激酶抑制剂（tyrosine kinase inhibitor, TKI）是EGFR突变的晚期非小细胞肺癌（non-small cell lung cancer, NSCLC）的一线治疗方案，但1年-2年内会出现耐药，后续治疗效果差。程序性死亡受体1(programmed cell death 1, PD-1)/程序性死亡配体1(programmed cell death ligand 1, PD-L1)抑制剂的出现极大地改变了肿瘤治疗的格局。然而，单药抗PD-1/PD-L1对EGFR突变的晚期NSCLC低应答或无应答，如何使EGFR突变的晚期NSCLC患者从抗PD-1/PD-L1治疗中获益是需要攻克的难关。本文主要就近5年来EGFR突变对NSCLC免疫状态影响的研究进展及相关的临床研究进行综述。更多还原

【Abstract】 The use of epidermal growth factor receptor(EGFR) tyrosine kinase inhibitor(TKI) is the first line treatment for EGFR-mutant advanced non-small cell lung cancer(NSCLC),but drug resistance will be acquired within 1-2 years,and the following treatment efficacy is poor.The invention of programmed cell death 1(PD-1)/programmed cell death ligand 1(PD-L1) inhibitors has dramatically changed the situation of tumor treatment.PD-1/PD-L1 inhibitors are less effective in patients with NSCLC harboring EGFR mutation.It is a challenge to make patients with EGFR-mutated advanced NSCLC benefit from anti-PD-1/PD-L1 therapy.In this paper,the research progress on the impact of EGFR mutation on the immune status of NSCLC and related clinical studies in recent 5 years are reviewed.更多还原